Precision medicine promises tailor-made treatments, but it is difficult to predict why a therapeutic agent that improves or restores one patient’s health can fail for another. Progress in precision medicine is being hindered by the lack of understanding of how processes at the molecular and cellular level impact function at the tissue, organ or system level. Similarly, results obtained in well-controlled laboratory experiments can be unreliable predictors of behavior seen in complex dynamic in-vivo environments.
NIST can help address these challenges by building upon its expertise in imaging, including quantitative cellular imaging, digital pathology, spectroscopic imaging, PET/CT, MRI, and image analytics to improve and create a new generation of tools that measure complex dynamic biological processes.
Workshop Goals:
For more information:
NIST - Gaithersburg Campus
Green Auditorium, Administration Bldg.
Poster Session - NIST Poster Hallway, Administration Bldg.
3:30 Poster Session Opens
4:00 Welcome
4:20 Poster talks - single slide, lightning talks
5:00 Posters
7:00 Adjourn
8:30 Introduction and welcome
8:45 What is Precision Medicine?
9:30 State of the Art in Vitro Imaging
10:15 BREAK
10:35 NIST collaboration: Measure/model/predict: Biomarker dynamics in pluripotent stem cell populations
10:55 NIST collaboration: Large Microscopy Imaging for Precision Medicine
11:15 Poster Session: Optional "guided tours"
12:15 LUNCH
1:00 Quantitative Imaging as a Tool for Precision Medicine
1:45 NIST collaboration: Medical Imaging Standards to Enable Precision Medicine
2:05 NIST collaboration: Nanoscale Fabrication and Optical Microscopy for Precision Medicine
2:25 Break
2:45 Break-out Session #1
3:30 Break-out Session #2
4:15 Break
4:30 Reports from break out team
5:30 Closing Remarks
5:45 ADJOURN
9:00 Optional lab tours
NIST Speakers
Keynote Speakers
SPEAKER BIOS |
---|
NIST Speaker Michael Halter received his Ph.D. in Bioengineering from the University of Washington at Seattle. In 2006 he started in the Biochemical Science Division at the National Institute of Standards and Technology (NIST) through a NRC postdoctoral fellowship. He is a currently a Staff Scientist in the Cell Systems Science Group where he applies quantitative optical microscopy to characterize dynamic and heterogeneous populations of cells. His research focuses imaging studies of pluripotent stem cells as well as approaches to assure the quality of image cytometry based measurements. He is currently an International Society for Advancement of Cytometry (ISAC) Scholar where he has developed online course material for assuring the quality of fluorescence microscopy based cell measurements. |
NIST Speaker Peter Bajcsy received his Ph.D. in Electrical and Computer Engineering in 1997 from the University of Illinois at Urbana-Champaign (UIUC) and a M.S. in Electrical and Computer Engineering in 1994 from the University of Pennsylvania (UPENN). He worked for machine vision, government contracting, and research and educational institutions before joining the National Institute of Standards and Technology (NIST) in 2011. At NIST, he has been leading a project focusing on the application of computational science in biological metrology, and specifically stem cell characterization at very large scales. Peter’s area of research is large-scale image-based analyses and syntheses using mathematical, statistical and computational models while leveraging computer science foundations for image processing, machine learning, computer vision, and pattern recognition. He has co-authored more than more than 34 journal papers and 9 books or book chapters, and close to 100 conference papers. |
NIST Speaker Samuel M. Stavis is a Project Leader in the NIST Center for Nanoscale Science and Technology. His research involves nanoscale particles, device technologies, and optical microscopy for applications in manufacturing and healthcare. |
NIST Speaker Katy Keenan is a Biomedical Engineer in the Magnetic Imaging group in the Applied Physics division in Boulder. As part of the MRI team, she developed MRI reference objects (phantoms) to assess the accuracy and comparability of MRI scanners, which have been successfully commercialized with multiple units sold. |
Keynote Speaker Victoria L. Seewaldt, M.D., is the Ruth Ziegler Professor and Chair of the Department of Population Science at City of Hope and Associate Cancer Center Director. Dr. Seewaldt was recently appointed to the NIH/NCI Board of Scientific Advisors. Dr. Seewaldt received her undergraduate degree in chemistry from Cornell University and attended medical school at University of California at Davis and received her residency and fellowship training from University of Washington and Fred Hutchinson Cancer Research Center. For the past 15 years, Dr. Seewaldt has led a multi-disciplinary bench to community research effort investigating the origins of triple-negative breast cancer at Duke University. It has been her greatest hope and desire to use research findings to improve the lives of women-of-color in the Durham and Triangle Community. Dr. Seewaldt now returns home to California to lead a program at City of Hope to prevention and early detection and to build a program focusing on the health sciences of disparities. Dr. Seewaldt was recently appointed to the NIH/NCI Board of Scientific Advisors. Currently Dr. Seewaldt is focusing on the role of diabetes in promoting epigenetic damage and breast cancer risk, particularly in Latina- and African-American women. Biomarkers identified in the laboratory are tested as predictors of short-term breast cancer risk in the high-risk women who participate in Dr. Seewaldt’s clinical trials. Importantly, the resources created by the community provide resources to advance the careers of young scholars who reflect the diversity of our communities. One of Dr. Seewaldt’s most important missions at City of Hope is to provide mentorship of young scholars and connect their career development to issues that are of vital importance to their communities. |
Keynote Speaker Dr. Thomas Baer is the Executive Director of the Stanford Photonics Research Center, a consulting professor in the Applied Physics Department, and an Associate Member of the Stem Cell Institute at Stanford University. His current scientific research is focused on developing imaging and biochemical analysis technology for exploring the molecular basis of human developmental biology and regenerative medicine, optogenetics, and developing new high-throughput technologies for protein engineering. Before joining Stanford, Dr. Baer founded Arcturus Bioscience, Inc. which he established in 1996, serving as the company's Chairman and CEO until January 2005. Prior to Arcturus, Dr. Baer was Vice President of Research at Biometric Imaging, where he led an interdisciplinary group developing instrumentation and reagents with applications in the areas of AIDS monitoring, bone marrow transplant therapy, and blood supply quality control. From 1981 to 1992 Dr. Baer was at Spectra-Physics, Inc., in Mountain View, California, where he held positions as a Research Scientist, Spectra-Physics Fellow, and Vice-President of Research. He was named entrepreneur of the year for emerging companies in Silicon Valley in 2000 by the Silicon Valley Business Journal and medical technology that he developed was chosen by Time Magazine as one of the top 10 medical advances in 2010. Dr. Baer holds over 70 patents and his commercial products have received many industry awards for design innovation. He has been elected to the status of Fellow in two international scientific societies, the American Association for the Advancement of Science and The Optical Society of America (OSA) and served as the President of OSA in 2009. In 2012 he received an honorary Doctor of Science degree from Heriot Watt University in Edinburgh, Scotland and was awarded the Robert E. Hopkins Leadership Award by the Optical Society of America. |
Keynote Speaker Robert Nordstrom is the Chief of Image Guided Interventions for the Cancer Imaging Program of NCI. He also serves as the Director of the Quantitative Imaging Network, a program designed to translate quantitative imaging tools for measuring or predicting response to therapy in clinical trials from development and optimization into clinical validation. Prior to his tenure with the federal government Dr. Nordstrom was the Vice President for Research in a Boston-based company bringing imaging methods to the detection of precancers of the cervix. He holds a doctorate from The Ohio State University in the physics of nonlinear laser spectroscopy. |